All AbMole products are for research use only, cannot be used for human consumption.
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin binds to GPNMB on tumors, the complex is internalized and MMAE is released via proteolytic cleavage of the vc linker in a lysosomal compartment. Tumor cell death occurs as a result of microtubule inhibition by MMAE with resultant cell cycle arrest.
Immobilized human GPNMB His at 2 ug/mL can bind Glembatumumab vedotin, the EC50 is 0.05407 ug/mL.
Glembatumumab vedotin (CR011-vcMMAE; 1.25-80 mg/kg; i.v.; every 4 days; for 16 days) shows short-term anti-tumor effects (inhibition of tumor growth) and long-term effects (complete regression) in human SK-MEL-2 and SK-MEL-5 melanoma xenografts.
| CAS Number | 1182215-65-1 |
| Solubility (25°C) | For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. |
| Storage | Store at ≤ -20℃ for up to 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Denintuzumab-MMAF
Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. |
| Enapotamab vedotin
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC). |
| Codrituzumab-MMAE (CHO)
Codrituzumab-MMAE is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). |
| Tisotumab Vedotin
Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer. |
| Vandortuzumab vedotin
Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
